Cleveland BioLabs, Inc. (CBLI) Receives an Increase in DoD Protectan CBLB502 Contract

October 6, 2009 9:31 AM EDT

Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced today that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) incresed the ongoing contract for the developmental studies related to Protectan CBLB502. The contract, awarded in April 2008, will increase from $8.86 million to $9.59 million.


Related Categories

Corporate News

Stocks Mentioned

CBLI 3.85

-0.05 -1.28%
Volume: 24,360
Track CBLI


Add Your Comment





Follow StreetInsider.com On Twitter